In the CRYSTAL trial, patients with metastatic CRC expressing EGFR were randomly assigned to receive irinotecan, fluorouracil and leucovorin (FOLFIRI) alone or in combination with cetuximab as a first-line therapy. This evidence concerns the gene EGFR and colorectal carcinoma.